AllianceBernstein’s Charles River Laboratories CRL Stock Holding History

AllianceBernstein’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$60.2M	Buy	301,993 +1,577	+0.5%	+$292K	0.02%	545
2025 Q4	$59.9M	Buy	300,416 +80,441	+37%	+$14.6M	0.02%	568
2025 Q3	$34.4M	Buy	219,975 +153,868	+233%	+$24.4M	0.01%	730
2025 Q2	$10M	Buy	66,107 +11,070	+20%	+$1.48M	﹤0.01%	1179
2025 Q1	$8.28M	Sell	55,037 -8,992	-14%	-$1.51M	﹤0.01%	1248
2024 Q4	$11.8M	Sell	64,029 -20,390	-24%	-$3.93M	﹤0.01%	1110
2024 Q3	$16.6M	Buy	84,419 +27,570	+48%	+$5.73M	0.01%	970
2024 Q2	$11.7M	Sell	56,849 -5,446	-9%	-$1.23M	﹤0.01%	1085
2024 Q1	$16.9M	Sell	62,295 -32,171	-34%	-$7.68M	0.01%	950
2023 Q4	$22.3M	Sell	94,466 -15,473	-14%	-$3.04M	0.01%	843
2023 Q3	$21.5M	Buy	109,939 +21,193	+24%	+$4.35M	0.01%	815
2023 Q2	$18.7M	Buy	88,746 +29,466	+50%	+$5.86M	0.01%	879
2023 Q1	$12M	Sell	59,280 -4,116	-6%	-$933K	0.01%	1019
2022 Q4	$13.8M	Sell	63,396 -30,620	-33%	-$6.69M	0.01%	948
2022 Q3	$18.5M	Sell	94,016 -9,091	-9%	-$1.96M	0.01%	856
2022 Q2	$22.1M	Sell	103,107 -2,472	-2%	-$604K	0.01%	831
2022 Q1	$30M	Buy	105,579 +39,361	+59%	+$12.1M	0.01%	765
2021 Q4	$24.9M	Sell	66,218 -1,688	-2%	-$656K	0.01%	872
2021 Q3	$28M	Buy	67,906 +974	+1%	+$405K	0.01%	814
2021 Q2	$24.8M	Sell	66,932 -16,812	-20%	-$5.61M	0.01%	857
2021 Q1	$24.3M	Buy	83,744 +816	+1%	+$227K	0.01%	863
2020 Q4	$20.7M	Sell	82,928 -1,294	-2%	-$308K	0.01%	861
2020 Q3	$19.1M	Buy	84,222 +20	+0%	+$4.15K	0.01%	816
2020 Q2	$14.7M	Buy	84,202 +5,062	+6%	+$808K	0.01%	856
2020 Q1	$9.99M	Sell	79,140 -3,800	-5%	-$570K	0.01%	914
2019 Q4	$12.7M	Buy	82,940 +50	+0.1%	+$6.92K	0.01%	985
2019 Q3	$11M	Sell	82,890 -1,163	-1%	-$156K	0.01%	1012
2019 Q2	$11.9M	Sell	84,053 -230	-0.3%	-$31.2K	0.01%	971
2019 Q1	$12.2M	Sell	84,283 -130	-0.2%	-$17.1K	0.01%	966
2018 Q4	$9.55M	Buy	84,413 +54,740	+184%	+$6.85M	0.01%	1010
2018 Q3	$3.99M	Sell	29,673 -440	-1%	-$54.3K	﹤0.01%	1435
2018 Q2	$3.38M	Buy	30,113 +415	+1%	+$44.9K	﹤0.01%	1530
2018 Q1	$3.17M	Sell	29,698 -460	-2%	-$49.6K	﹤0.01%	1503
2017 Q4	$3.3M	Sell	30,158 -160	-0.5%	-$17.4K	﹤0.01%	1501
2017 Q3	$3.27M	Buy	30,318 +10	+0%	+$1.03K	﹤0.01%	1496
2017 Q2	$3.07M	Buy	30,308 +410	+1%	+$37.7K	﹤0.01%	1529
2017 Q1	$2.69M	Sell	29,898 -66	-0.2%	-$5.61K	﹤0.01%	1598
2016 Q4	$2.28M	Sell	29,964 -343	-1%	-$26.1K	﹤0.01%	1729
2016 Q3	$2.53M	Sell	30,307 -157	-0.5%	-$13.2K	﹤0.01%	1598
2016 Q2	$2.51M	Buy	30,464 +90	+0.3%	+$7.41K	﹤0.01%	1509
2016 Q1	$2.31M	Sell	30,374 -50	-0.2%	-$3.7K	﹤0.01%	1488
2015 Q4	$2.45M	Sell	30,424 -240	-0.8%	-$17.3K	﹤0.01%	1454
2015 Q3	$1.95M	Sell	30,664 -910	-3%	-$65.3K	﹤0.01%	1666
2015 Q2	$2.22M	Sell	31,574 -1,356	-4%	-$100K	﹤0.01%	1701
2015 Q1	$2.61M	Sell	32,930 -950	-3%	-$70.1K	﹤0.01%	1532
2014 Q4	$2.16M	Sell	33,880 -300	-0.9%	-$18.8K	﹤0.01%	1705
2014 Q3	$2.04M	Sell	34,180 -2,838	-8%	-$162K	﹤0.01%	1700
2014 Q2	$1.98M	Sell	37,018 -2,142	-5%	-$118K	﹤0.01%	1779
2014 Q1	$2.36M	Buy	39,160 +2,042	+6%	+$119K	﹤0.01%	1584
2013 Q4	$1.97M	Sell	37,118 -1,477	-4%	-$74.2K	﹤0.01%	1715
2013 Q3	$1.78M	Buy	38,595 +3,030	+9%	+$139K	﹤0.01%	1761
2013 Q2	$1.46M	Buy	+35,565	New	+$1.52M	﹤0.01%	1841

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein's CRL Position: Q1 2026 in Review

AllianceBernstein increased its Charles River Laboratories (CRL) stake by 0.52% in Q1 2026, buying an estimated $292K and bringing the position to 301,993 shares worth $60.2M. The position accounts for 0.02% of the portfolio, ranked #545.

AllianceBernstein first reported a position in CRL in Q2 2013 and has held it in 52 quarters since. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

AllianceBernstein held 301,993 shares of Charles River Laboratories worth $60.2M as of Q1 2026.
AllianceBernstein bought 1,577 Charles River Laboratories shares in Q1 2026, an estimated $292K.
Charles River Laboratories made up 0.02% of AllianceBernstein's portfolio in Q1 2026, its #545 holding.
AllianceBernstein first reported a position in Charles River Laboratories in Q2 2013 and has held it in 52 quarters since.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.